Search
Partnering-Animal-Health.pdf
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Boehringer Ingelheim and the Lieber Institute for Brain Development To Collaborate to Develop Centrally Acting COMT Inhibitors For the Treatment of Neuropsychiatric Disorders
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Jardiance® (empagliflozin) Reduces Risk for CV Death | BI US
Analyses show risk reductions were consistent across age groups for CV outcomes with JARDIANCE compared with placebo. View ISI, PI & Med Guide.
Boehringer welcomes 2023 Gold Report
Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment
Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Boehringer Ingelheim announces InPedILD PhaseIII trial results
Our Businesses
Our Businesses
Update on sNDA for fibrosing ILD in children and adolescents
Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis, discusses the FIBRONEER™ global clinical program
new_health_insurance_marketplace_coverage_options_and_your_health_coverage.pdf
Innovation in Immunology | Human Health | Boehringer Ingelheim US
BI's Immunology & Respiratory research combines our ability to address unmet medical needs with pioneering patient-centered approaches.
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
How Simulation is Changing the Game in Biotherapeutic Drug Development
How Simulation is Changing the Game in Biotherapeutic Drug Development
Our culture
Our culture reflects who we are and is reflected in Our FOCUS and strong belief in Diversity, Equity and Inclusion as well as Sustainable Development.
Vampire Bats & Rabies: A Potential New Threat | Boehringer Ingelheim US
Read more on the emerging threat of rabid vampire bats in the Southern US. Helping prevent this disease preserves the lives of livestock worldwide.
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
CIA Reporting Requirements
CIA Reporting Requirements
2024 HBA Luminary from Boehringer Ingelheim recognized for putting patients first
Nicole Forman receives notable award for her commitment to health equity.
Jardiance® (empagliflozin) Reduced Risk of Progressive Kidney Disease
Data shows JARDIANCE reduced the risk for new-onset or worsening kidney disease in adults with T2D with established CV disease. View ISI, PI & Med Guide.
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Arising Vaccines to Help Zoo Elephants | Boehringer Ingelheim US
Find out how Boehringer Ingelheim is developing vaccines to help North African zoo elephants suffering from deadly infections and illness.
Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US
BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.